{{Drugbox
| verifiedrevid =
| IUPAC_name = (3''R'')-3-(4-chlorophenyl)-4-<nowiki>[[[</nowiki>(1''S'')-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
| image = Arbaclofen placarbil.svg
| width = 260
<!--Clinical data-->
| tradename = 
| Drugs.com =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = N/A
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = Development terminated
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CAS_number = 847353-30-4
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| ChEMBL = 2107312
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| PubChem = 11281011
| ChemSpiderID = 9456008
| smiles = CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl
| StdInChI = 1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
| StdInChIKey = JXTAALBWJQJLGN-KSSFIOAISA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII =
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08861
| ChEMBL_Ref = {{ebicite|correct|EBI}}
<!--Chemical data-->
| C=19 | H=26
| Cl=1 | N=1
| O=6
| molecular_weight = 399.86 g/mol
}}

'''Arbaclofen placarbil''' ({{IPAc-en|ɑːr|ˈ|b|æ|k|l|oʊ|f|ɛ|n|_|p|l|ə|ˈ|k|ɑːr|b|ɪ|l}} {{respell|ar|BAK|loh|fen|_|plə|KAR|bil}}, also known as '''XP19986''') is a [[prodrug]] of ''R''-[[baclofen]]. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with [[gastroesophageal reflux disease|GERD]] and spasticity due to [[multiple sclerosis]]; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in [[Phases of clinical research#Phase III|phase III]] clinical trials.<ref name="Results">http://investor.xenoport.com/releasedetail.cfm?ReleaseID=765868</ref>

It is being developed as an addiction medicine to treat alcoholism. <ref> https://inews.co.uk/essentials/news/business/pill-replaces-alcohol-aims-end-middle-class-drinking-epidemic/ </ref>
==See also==
* [[Gabapentin enacarbil]]
* [[Lesogaberan]]

==References==
{{Reflist|2}}


{{Muscle relaxants}}
{{Drugs for peptic ulcer and GORD}}
{{GABAergics}}
{{Channel blockers}}

[[Category:Abandoned drugs]]
[[Category:Amino acids]]
[[Category:Calcium channel blockers]]
[[Category:Chloroarenes]]
[[Category:GABA analogues]]
[[Category:GABAB receptor agonists]]
[[Category:Prodrugs]]

{{gastrointestinal-drug-stub}}
{{musculoskeletal-drug-stub}}